Nivolumab (NIVO) plus ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
No Thumbnail Available
Identifiers
Date
2021-12-10
Authors
Reck, M.
Ciuleanu, T. E.
Pluzanski, A.
Lee, J. S.
Caro, R. Bernabe
Linardou, H.
Burgers, J.
Gallardo, C.
Nishio, M.
Peters, S.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
